Video

Managing Advanced Lung Cancer in the Future

Transcript:

Philippa Cheetham, MD: Obviously, patients are concerned about outcomes and survival, and whether they’re going to be cured or not cured. Do you think it’s fair to say that, regardless of cure, we can guarantee a patient that they don’t need to be in pain and that they don’t need to be suffering with nausea and overwhelming side effects of the disease? Have we gotten to a point, now in palliative care, where we can deal with the symptoms that have a huge impact on patient quality of life, not just life expectancy?

Sara F. Martin, MD: Yes. It’s fair to say that for most patients, or all patients, we should be able to guarantee that you’re not going to have severe, uncontrollable pain. That doesn’t mean that you might not have aches and pains. We should be able to guarantee that you’re not constantly nauseated and constantly vomiting. Those are things that we should be able to guarantee for all patients at this point in medical care.

Philippa Cheetham, MD: And where do you see the future of all these treatment armamentariums? Do you think that we still have a long way to go with lung cancer management?

Sara F. Martin, MD: In terms of symptoms for patients?

Philippa Cheetham, MD: Yes.

Sara F. Martin, MD: I think there will always be new symptoms. The immunotherapies are a great new treatment option. But they have a whole different set of symptoms that patients can develop that we didn’t see with more traditional chemotherapy. So, I think as newer agents come on the market, we’ll be faced with newer symptoms or things to manage from that treatment. It’s really about learning what those are and, then, how to manage them.

Philippa Cheetham, MD: Dr. Osmundson, we know that with the excessive use of antibiotics, there’s now a whole generation of superbugs that have morphed into being able to survive in an environment where they have developed antibiotic resistance. We’re having to develop more and more drugs to deal with that. Do you think that cancer is going to beat all of us? Do you think we’re going to start seeing more aggressive forms that may evolve into being resistant to immunotherapies? The more we throw at these tumor cells, are they likely to potentially evolve into becoming resistant where we’re just kind of chasing it further and further down the line? Or, is this all cyber talk?

Evan C. Osmundson, MD, PhD: I certainly think that with respect to any individual patient’s tumor, it’s a microevolutionary process. You challenge it with different therapies. There will be a subset of cells that will be resistant. I should say that they may or may not be resistant. So, certainly, that’s going to happen based on the kinetics of the tumor. In the long-term, though, I do think that there’s hope for potentially curing stage IV patients. I think we’ve seen it in other diseases. In particular, like head and neck cancer, for example, stage IV patients can potentially be cured. We see it in hodgkins lymphoma. In patients who are technically stage IV, we have cure ability rates greater than 90%. So, I just think that we need more research and more time. Ultimately, with the right teams and the right minds, we’ll be able to enact more cures.

Philippa Cheetham, MD: Well, maybe within a few years, the drug companies will have invented a lung cancer vaccine that we can give to all of our patients. But, in the meantime, thank you so much for all of the work that you do in taking care of patients and educating everyone who is tuning into CURE Connections® today. Thank you so much.

Transcript Edited for Clarity

Related Videos
Image of a woman with long red hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man wearing a black suit and tie.
Image of a man with rectangular glasses and a goatee.
Image of a doctor with dark curly hair and rectangular glasses.
Image of a woman with a brown hair tied into a bun.
Image of a woman with blond hai
Related Content
Image of a person in a field with their hands outstretched to the sky.
October 26th 2024

God Helped Me See a Better Side During Kidney Cancer

Barbara Van Nostrand
When I was diagnosed with a rare and aggressive kidney cancer, I turned to God and He has helped me through my journey, each step of the way.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of a man with dark hair and rectangular glasses.
October 22nd 2024

In Cancer, the Whole Is Greater Than the Sum of Its Parts

Burt Rosen
In addition to receiving my traditional cancer treatments, I also opt for integrative medicines, which have helped my mental health.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of pills forming side effects text.
October 21st 2024

Symproic May Prevent Opioid-Induced Constipation

Alex Biese
For patients with cancer, Symproic may prevent constipation and improve quality of life.
Two illustrations of people with tumors in the throat and jaw area.
October 19th 2024

Similar Survival Shown With Radiation Versus Robotic Surgery in HNC

Ashley Chan
Patients with a head and neck cancer subtype did not show differences in survival outcomes when treated with radiation versus transoral robotic surgery.